For Novartis, 2012 Is Set To Be A Bumpy Ride

By John Davis / Email the Author / Health News Daily Jan. 27, 2012
Word Count: 896 / Article # 29120127001

Executive Summary

With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 896-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: For Novartis, 2012 Is Set To Be A Bumpy Ride

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Health News Daily will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

For Novartis, 2012 Is Set To Be A Bumpy Ride

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 3

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article